Edition:
United Kingdom

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

11.41USD
25 Apr 2018
Change (% chg)

$-0.63 (-5.23%)
Prev Close
$12.04
Open
$11.95
Day's High
$12.24
Day's Low
$11.38
Volume
144,947
Avg. Vol
130,694
52-wk High
$14.99
52-wk Low
$2.69

Chart for

About

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare... (more)

Overall

Beta: 2.35
Market Cap(Mil.): $581.34
Shares Outstanding(Mil.): 51.77
Dividend: --
Yield (%): --

Financials

  DRNA.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -3.66 -- --
ROI: -82.57 -0.73 12.97
ROE: -112.52 -2.77 14.84

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

UPDATE 2-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

CORRECTED-Biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

BRIEF-Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals

* ALNYLAM REACHES SETTLEMENT AGREEMENT WITH DICERNA PHARMACEUTICALS RESOLVING TRADE SECRET MISAPPROPRIATION AND OTHER PENDING LITIGATION

20 Apr 2018

BRIEF-Dicerna Pharma Files ‍Prospectus Related To Offering

* DICERNA PHARMACEUTICALS INC FILES ‍PROSPECTUS RELATED TO OFFERING UP TO 24.5 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING​ Source text: (http://bit.ly/2FKmcfn) Further company coverage:

19 Mar 2018

BRIEF-Dicerna Reports Qtrly Loss Per Share Of $0.90

* DICERNA REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE

08 Mar 2018

BRIEF-Ecor1 Capital Llc Reports a 9.4 Percent Passive Stake In Dicerna Pharmaceuticals

* ECOR1 CAPITAL, LLC REPORTS A 9.4 PERCENT PASSIVE STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 20, 2017 Source text: (http://bit.ly/2Ac7p5t) Further company coverage:

03 Jan 2018

BRIEF-RA Capital Management LLC Reports 9.9 Pct Stake In Dicerna Pharmaceuticals

* RA CAPITAL MANAGEMENT LLC REPORTS 9.9 PERCENT STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 18 - SEC FILING

20 Dec 2017

BRIEF-Bain Capital Life Sciences Fund Reports 15.7 Percent Stake In Dicerna Pharmaceuticals

* BAIN CAPITAL LIFE SCIENCES FUND L.P. REPORTS 15.7 PERCENT STAKE IN DICERNA PHARMACEUTICALS INC AS ON DEC 18 - SEC FILING

19 Dec 2017

Earnings vs. Estimates